This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Stifel sees path towards differentiation for Viridian after Amgen data
Stifel analyst Alex Thompson notes that Amgen (AMGN) announced positive topline results for the Phase 3 on-body infusion study of Tepezza achieving a 77% rate of proptosis response, which comes in higher on both an absolute and placebo-adjusted basis compared to Viridian Therapeutics’ (VRDN) elegrobar. However, with elegrobart’s subcutaneous injection profile versus on-body infusion, the firm sees a path towards differentiation in the market, says the analyst, who has a Buy rating on Viridian shares.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
Disclaimer & DisclosureReport an Issue
- Evercore cuts Viridian price target, removes from ‘Tactical Outperform’ list
- Viridian Therapeutics price target lowered to $37 from $44 at Wedbush
- Viridian Therapeutics price target lowered to $20 from $29 at Wells Fargo
- Viridian Therapeutics price target lowered to $36 from $41 at Goldman Sachs
- Viridian Therapeutics price target lowered to $22 from $34 at H.C. Wainwright
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
